Бастиан Блоэм - Нестареющее тело. Научное исследование о том, как защитить свои тело и мозг и не допустить развития неврологических заболеваний

60. Bendor J, Logan T, Edwards RH. The function of a-synuclein. Neuron. 2013;79(6):10.1016/j.neuron.2013.1009.1004.

61. Smith WW, Pei Z, Jiang H, Dawson VL, Dawson TM, Ross CA. Kinase activity of mutant LRRK2 mediates neuronal toxicity. Nature Neuroscience. 2006;9(10): 1231–1233; Martin I, Kim JW, Dawson VL, Dawson TM. LRRK2 pathobiology in Parkinson’s disease. Journal of Neurochemistry. 2014;131(5):554–565.

62. Martin I, Kim JW, Dawson VL, Dawson TM. LRRK2 pathobiology in Parkinson’s disease. Journal of Neurochemistry. 2014;131(5):554–565.

63. Moses H, Dorsey ER, Matheson DM, Thier SO. Financial anatomy of biomedical research. JAMA. 2005;294(11): 1333–1342; Moses H, Matheson DM, Cairns-Smith S, George BP, Palisch C, Dorsey E. The anatomy of medical research: US and international comparisons. JAMA . 2015;313(2):174–189.

64. Moses H, Dorsey ER, Matheson DM, Thier SO. Financial anatomy of biomedical research. JAMA. 2005;294(11):1333–1342.

65. 2018 PhRMA Annual Membership Survey. Pharmaceutical Research and Manufacturers of America. July 26, 2018. www.phrma.org/ report/2018-phrma-annual-membership-survey. Accessed June 28, 2019.

66. Moses H, Dorsey ER, Matheson DM, Thier SO. Financial anatomy of biomedical research. JAMA. 2005;294(11): 1333–1342; Moses H, Matheson DM, Cairns-Smith S, George BP, Palisch C, Dorsey E. The anatomy of medical research: US and international comparisons. JAMA . 2015;313(2):174–189.

67. Moses H, Dorsey ER, Matheson DM, Thier SO. Financial anatomy of biomedical research. JAMA. 2005;294(11):1333–1342.

68. Cannon JR, Greenamyre JT. Gene-environment interactions in Parkinson’s disease: specific evidence in humans and mammalian models. Neurobiology of Disease. 2013;57:38–46.

69. Там же.

70. Там же.

71. Di Maio R, Hoffman EK, Rocha EM, et al. LRRK2 activation in idiopathic Parkinson’s disease. Science Translational Medicine. 2018; 10(451); Cannon JR, Greenamyre JT. Gene-environment interactions in Parkinson’s disease: specific evidence in humans and mammalian models. Neurobiology of Disease. 2013;57:38–46; Lee J-W, Cannon JR. LRRK2 mutations and neurotoxicant susceptibility. Experimental Biology and Medicine. 2015;240(6):752–759.

72. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery, and Psychiatry. 1992;55(3):181–184; Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G. Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology. 2016;86(6):566–576.

73. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson’s disease: a clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery, and Psychiatry . 1992;55(3):181–184; Schrag A, Ben-Shlomo Y, Quinn N. How valid is the clinical diagnosis of Parkinson’s disease in the community? Journal of Neurology, Neurosurgery & Psychiatry. 2002;73(5):529.

74. Rizzo G, Copetti M, Arcuti S, Martino D, Fontana A, Logroscino G. Accuracy of clinical diagnosis of Parkinson disease: a systematic review and meta-analysis. Neurology. 2016;86(6):566–576.

75. MDS-UPDRS. International Parkinson and Movement Disorder Society. July 1, 2008. www.movementdisorders.org/MDS-Files1/PDFs/Rating-Scales/MDS-UPDRS_English_FINAL_Updated_June2019.pdf.

76. Dolan KA. Andy Grove’s last stand. Forbes. January 11, 2008. www. forbes.com/forbes/ 2008/0128/070.html#462dbe0b641e. Accessed June 28, 2019.

77. Little MA, McSharry PE, Roberts SJ, Costello DA, Moroz IM. Exploiting nonlinear recurrence and fractal scaling properties for voice disorder detection. BioMedical Engineering OnLine. 2007;6(1):23.

78. Little MA, McSharry PE, Hunter EJ, Spielman J, Ramig LO. Suitability of dysphonia measurements for telemonitoring of Parkinson’s disease. IEEE Transactions on Biomedical Engineering. 2009;56(4):1015–1022.

79. Tsanas A, Little MA, McSharry PE, Spielman J, Ramig LO. Novel speech signal processing algorithms for high-accuracy classification of Parkinson’s disease. IEEE Transactions on Biomedical Engineering . 2012;59(5):1264–1271.

80. Little MA, McSharry PE, Hunter EJ, Spielman J, Ramig LO. Suitability of dysphonia measurements for telemonitoring of Parkinson’s disease. IEEE Transactions on Biomedical Engineering . 2009;56(4):1015–1022; Tsanas A, Little MA, McSharry PE, Spielman J, Ramig LO. Novel speech signal processing algorithms for high-accuracy classification of Parkinson’s disease. IEEE Transactions on Biomedical Engineering . 2012;59(5):1264–1271; Tsanas A, Little MA, McSharry PE, Ramig LO. Accurate telemonitoring of Parkinson’s disease progression by noninvasive speech tests. IEEE Transactions on Biomedical Engineering. 2010;57(4):884–893; Tsanas A, Little MA, McSharry PE, Ramig LO. Nonlinear speech analysis algorithms mapped to a standard metric achieve clinically useful quantification of average Parkinson’s disease symptom severity. Journal of the Royal Society Interface . 2011;8(59):842–855.

81. Little MA. A test for Parkinson’s with a phone call [видео]. TED Global 2012. June 2012. www.ted.com/talks/max_little_a_test_for_ parkinson_s_with_a_phone_call. Accessed June 28, 2019.

82. Arora S, Venkataraman V, Zhan A, et al. Detecting and monitoring the symptoms of Parkinson’s disease using smartphones: a pilot study. Parkinsonism & Related Disorders. 2015;21(6):650–653.

83. Там же.

84. Zhan A, Mohan S, Tarolli C, et al. Using smartphones and machine learning to quantify Parkinson disease severity: the mobile Parkinson disease score. JAMA Neurology. 2018;75(7):876–880.

85. Bot BM, Suver C, Neto EC, et al. The mPower study, Parkinson disease mobile data collected using ResearchKit. Scientific Data. 2016;3:160011.

86. McLeonida. ResearchKit demo by Jeff Williams at Apple special event, March 2015 [видео]. YouTube. March 11, 2015. www.youtube.com/ watch?v=O0gcEFjQNGk. Accessed June 28, 2019.

87. Dorsey ER, Beck CA, Adams M, et al. Communicating clinical trial results to research participants. Archives of Neurology. 2008;65(12):1590–1595.

88. Writing Group for the NINDS Exploratory Trials in Parkinson Disease Investigators. Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial. JAMA. 2015;313(6):584–593.

89. Dorsey ER, Chan Y-FY, McConnell MV, Shaw SY, Trister AD, Friend SH. The use of smartphones for health research. Academic Medicine. 2017;92(2):157–160.

90. Turakhia MP, Desai M, Hedlin H, et al. Rationale and design of a largescale, app-based study to identify cardiac arrhythmias using a smartwatch: the Apple Heart Study. American Heart Journal . 2019;207:66–75.

91. Farr C. The Apple Watch just got a lot better at tracking symptoms of Parkinson’s disease. CNBC. June 9, 2018. www.cnbc.com/2018/06/09/ apple-watch-adds-tech-to-track-parkinsons-disease.html. Updated June 10, 2018. Accessed November 10, 2018.

92. Collaboration with Verily aims to deepen Parkinson’s understanding through digital health tools. FoxFeed Blog. May 9, 2018. www.michaeljfox. org/news/collaboration-verily-aims-deepen-parkinsons-understanding-through-digital-health-tools?collaboration-with-verily-aims-to-deepen-parkinson-understanding-through-digital-health-tools=. Accessed June 28, 2019; About the study. Personalized Parkinson Project. www. parkinsonopmaat.nl/studie. Accessed May 20, 2019.